Background Secukinumab has demonstrated significant efficacy with a good safety profile through 1 year in plaque psoriasis. Given the chronic nature of this disease, long-term follow-up is needed to evaluate psoriasis therapies fully. Objectives To determine the long-term (3-year) efficacy and safety of secukinumab in moderate-to-severe psoriasis. Methods Patients completing 52 weeks of secukinumab treatment in the SCULP-TURE core study entered an extension in which they continued the same doubleblind regimens. Dosing regimens included a fixed-interval schedule (FI; every 4 weeks) and retreatment as needed (RAN), in which patients were withdrawn from secukinumab and received placebo until the start of relapse, at which time secukinumab every 4 weeks was reinitiated. The study was registered with number NCT01640951. Results In total 168 patients receiving secukinumab 300 mg FI and 172 receiving secukinumab 300 mg RAN entered the extension. Secukinumab 300 mg FI sustained high efficacy: at the end of year 3, the proportion of responders achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) was 63Á8%, and of PASI 100 responders it was 42Á6%. The mean absolute PASI remained low (2-4) from week 52 to week 152 with 300 mg FI, with approximately two-thirds of patients reporting no impact of skin disease on their lives (Dermatology Life Quality Index of 0 or 1). Improvements in overall and subscale scores on all quality-of-life instruments were well sustained. As in the core study, FI dosing was consistently more efficacious than RAN. No new safety signals were identified to year 3. Conclusions Secukinumab 300 mg FI sustained high responses and improved quality of life with no new safety concerns through 3 years.
What does this study add?
• Follow-up data to 3 years confirm that the high responses initially achieved with secukinumab are sustained over time.
• A large proportion (63Á8%) of patients treated with fixed-interval secukinumab had ≥ 90% improvement in Psoriasis Area and Severity Index at year 3, with approximately two-thirds reporting no impact of skin disease on quality of life.
• Patient-perceived impairment of overall health status remained consistently low.
No new or unexpected safety concerns emerged.
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, has been shown to have significant efficacy in the treatment of moderate-to-severe psoriasis and psoriatic arthritis, demonstrating a rapid onset of action and sustained responses with a favourable safety profile. [1] [2] [3] [4] [5] [6] [7] [8] Clinical trial data on additional agents that target IL-17A or its receptor have recently been published, providing short-term efficacy and safety findings ranging from 12 to 60 weeks. [9] [10] [11] [12] However, given the chronic and potentially lifetime course of moderate-to-severe plaque psoriasis, doubleblind data collected over multiple years of treatment are needed to evaluate more fully the efficacy and safety profiles of psoriasis therapies. In particular, treatments with novel mechanisms of action, such as IL-17A inhibitory therapies, require long-term study to characterize their safety profiles adequately. The SCULPTURE study was conducted to compare fixedinterval (FI; every 4 weeks) and retreatment-as-needed (RAN) secukinumab maintenance dosing in the treatment of moderate-to-severe plaque psoriasis. Results of the study to 52 weeks have been published; FI was identified as the optimal maintenance regimen during that period. 7 In recognition of the need for long-term psoriasis therapy, an extension study was planned to evaluate each dosing regimen beyond 1 year. Efficacy, safety and health-related quality of life (HRQOL) data from a total of 3 years of double-blind extension treatment are reported here.
Patients and methods

Study design
Patients who completed 52 weeks of treatment in the SCULP-TURE and STATURE studies entered a multicentre extension study (NCT01640951) conducted to collect additional safety, tolerability and efficacy data for secukinumab. The data presented are for the patients from the SCULPTURE core study who enrolled in the extension, and cover 3 years of treatment from core study baseline. SCULPTURE was a randomized, double-blind, parallel-group, 52-week trial designed to compare different secukinumab maintenance treatment regimens in patients with moderate-tosevere plaque psoriasis (Fig. 1a) . 7 Patients who received subcutaneous secukinumab 300 mg or 150 mg in FI or RAN maintenance regimens in SCULPTURE continued the same double-blind secukinumab dose and regimen via prefilled syringe in the extension (Fig. 1b) . The first treatment dose of the extension was at week 52. The extension study did not employ randomization, and patients were not required to achieve ≥ 75% improvement in baseline Psoriasis Area and Severity Index (PASI 75) at the end of the core study to enrol. The last blinded dose was at week 152.
Patients who received subcutaneous secukinumab 300 mg every 4 weeks in the maintenance period of the STATURE core study were also eligible to enter the extension and received open-label treatment in a separate study arm from week 52 onward. 13 To focus on double-blind data for the recommended secukinumab dose per label (300 mg), the analyses reported here will include only those patients from the SCULPTURE core study who enrolled in the extension and continued treatment with secukinumab 300 mg, either as FI or RAN.
Inclusion and exclusion criteria
Eligibility criteria for the SCULPTURE core study included age ≥ 18 years and a diagnosis (≥ 6 months prior to randomization) of chronic moderate-to-severe plaque psoriasis, defined as all of the following: PASI score ≥ 12; Investigator's Global Assessment, 2011 modified version (IGA mod 2011) score of 3 or 4; and body surface area affected ≥ 10%. Additionally, patients were required to have a history of inadequate psoriasis control with any of the following: topical treatments, phototherapy, systemic therapy or a combination of these therapies. 7 Use of concomitant psoriasis therapy during the study was prohibited, with the exception of topical corticosteroids applied to the face, scalp and/or genitoanal area for at most 14 consecutive days. Patients were eligible to continue into the extension if they were expected to benefit from participation in the extension study, as assessed by the patient and investigator.
Treatment
Patients in the extension study continued their maintenance treatment from the SCULPTURE core study, namely subcutaneous secukinumab 300 mg or 150 mg in a FI or RAN regimen. The FI involved dosing once every 4 weeks, and in the RAN regimen patients received placebo until the start of relapse, defined as loss of ≥ 20% of maximum PASI improvement vs. baseline plus loss of PASI 75 response. When criteria for start of relapse were fulfilled, the patient would then receive active secukinumab at the originally randomized dose at scheduled study visits (i.e. every 4 weeks) until regain of PASI 75 response, at which point in time the patient would start receiving placebo again.
Outcomes
The primary objective of this study was to assess the longterm safety and tolerability of secukinumab. The secondary objective was to evaluate long-term efficacy, as measured by PASI 75/90/100 and IGA 0 (clear) or 1 (almost clear) responses, mean PASI, total and subscale scores on the Dermatology Life Quality Index (DLQI), and scores on the EuroQoL 5-Dimension Health Questionnaire 3-level version (EQ-5D-3L) descriptive system and visual analogue scale.
Assessments
Efficacy assessment instruments included PASI [a composite evaluation instrument for psoriasis severity, with subscores for erythema, induration, scaling and percentage of body surface area affected; total score range from 0 (best) to 72 (worst)] 14 and a modified 5-point IGA [a static instrument for rating the clinician's impression of the overall severity of the psoriasis, on a scale from 0 (clear skin) to 4 (severe disease); Appendix S1; see Supporting Information]. 15 PASI and IGA mod 2011 assessments were conducted every 4 weeks from week 52 onward. The DLQI and EQ-5D-3L were used to evaluate the effects of treatment on HRQOL. The DLQI consists of a 10-item, dermatology-specific instrument with a range of 0-30 points; higher scores indicate worse HRQOL, with a score of 0 or 1 representing no effect of skin problems on a patient's HRQOL. 16 DLQI items are grouped into six subscales assessing the impact of skin disease as related to symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The EQ-5D-3L is a generic HRQOL instrument that comprises a descriptive system and a visual analogue scale. For the descriptive system, patients describe their level of impairment in each of five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with three possible ratings (no problems, some problems/moderate problems, and severe problems 
Statistical methods
For all efficacy assessments, summary statistics were calculated by visit and treatment group. Proportions of patients with PASI 75/90/100 response, IGA mod 2011 0/1 response, and DLQI 0/1 response (in the DLQI total and subscale scores); proportions of patients reporting no impact of disease on each EQ-5D-3L domain; and absolute mean change from baseline in EQ-5D-3L visual analogue scale score were all analysed using observed values without imputation of any missing values. Multiple imputation of missing data was used in supportive analyses of PASI 75/90/100 response and IGA mod 2011 0/1 response. Adverse events are reported as exposureadjusted incidence rates (incidence per 100 patient-years).
Study oversight
The ethical conduct of the study and compliance with applicable regulations were implemented as disclosed in the core study report. 7 
Results
Patient disposition and baseline characteristics
In total 642 patients from the SCULPTURE core study entered the extension study, including 168 in the secukinumab The adverse events leading to discontinuation in the 300 mg RAN group, by MedDRA preferred term, were C. difficile colitis, psoriasis (i.e. worsening psoriasis, two cases), pancreatitis acute, dermatitis, psoriatic arthropathy (two cases), limb crushing injury, arthralgia, dyspnoea, intervertebral disc compression, and otitis media acute with pharyngitis.
c One patient completed the study because a protocol amendment extending the treatment period beyond week 156 had not been approved at that study site by week 156 of the patient's participation.
300 mg FI arm and 172 in the secukinumab 300 mg RAN arm (Fig. 2) . The patient demographics and clinical characteristics at core study baseline (week 0) were similar between the treatment arms ( Table 1) .
Number and frequency of active injections
The mean total number of active secukinumab injections from week 52 through week 156 was 49Á1 in the secukinumab 300 mg FI group and 25Á8 in the secukinumab 300 mg RAN group, representing approximately 50% lower secukinumab exposure in the RAN group compared with the FI group. The mean time interval between active secukinumab injections in the FI group was 4Á1 weeks (median 4Á0, range 3Á9-10Á1), corresponding to the once-monthly secukinumab dosing schedule. The mean time interval between active secukinumab injections in the RAN group was 10Á4 weeks (median 8Á0, range 3Á4-111Á4).
Efficacy
Secukinumab FI dosing sustained high PASI 75/90/100 and IGA mod 2011 0/1 response levels from week 52 out to year 3 in the observed data analysis (Fig. 3 and Fig. S1 ; see Supporting Information). At week 52, 43Á8% [95% confidence interval (CI) 36Á1-51Á8] of patients in the secukinumab 300 mg FI arm had clear skin (PASI 100). This response was well maintained, with a response rate at year 3 of 42Á6% (95% CI 34Á4-51Á2). A majority (68Á5%, 95% CI 60Á7-75Á5) of patients receiving secukinumab 300 mg FI at week 52 achieved PASI 90. This response was well preserved at 3 years, with 63Á8% (95% CI 55Á3-71Á6) of patients maintaining a PASI 90 response. As reported in the core study, the 300 mg FI regimen was better than the 300 mg RAN regimen in maintaining efficacy. The PASI 100 response rate in the 300 mg RAN group was 5Á3% (95% CI 2Á6-10Á2) at week 52 and 3Á8% (95% CI 1Á4-9Á1) at year 3; the PASI 90 response was 14Á8% (95% CI 10Á0-21Á3) at week 52 and 13Á0% (95% CI 8Á0-20Á2) at year 3. The results of the multiple imputation analysis were not markedly different from those of the observed analysis for both regimens ( Fig. S2 ; see Supporting Information). The mean absolute PASI remained low for up to 3 years (Fig. 4) . As expected, patients receiving the 300 mg FI dose achieved a high level of psoriasis control, with a mean PASI in the range of 2À4 during year 2 and year 3.
Quality of life
The high degree of disease control with secukinumab 300 mg FI was reflected in patient-reported HRQOL. During years 2 and 3, approximately two-thirds of the patients in this group reported a DLQI total score of 0 or 1 (week 52: 72Á7%, 95% CI 65Á2-79Á2%; week 104: 64Á7%, 95% CI 56Á5-72Á1; week 140: 68Á3%, 95% CI 59Á9-75Á7), indicating no impact of skin disease on their lives (Fig. 5a ). For FI patients who did not maintain a DLQI 0/1 response between years 1 and 3, the majority (69%) shifted to a year 3 DLQI score of 2-5, indicating a small effect of disease on their quality of life. The DLQI total score remained at or close to 1 in the 300 mg FI treatment group during the follow-up period (Fig. 5b) , with a median value of 1Á0 (95% CI 0Á5-1Á0) at week 52, 1Á5 (95% CI 1Á0-1Á5) at week 104, and 1Á0 (95% CI 0Á5-1Á5) at week 140. All DLQI subscales showed well-sustained responses through 3 years ( Fig. S3 ; see Supporting Information). As expected, there was a lesser DLQI response with the RAN regimen than with the FI regimen; the percentage of patients in the secukinumab 300 mg RAN group with a DLQI total score of 0 or 1 was 36Á8% (95% CI 29Á7-44Á6) at week 52, 38Á4% (95% CI 30Á5-46Á8) at week 104 and 41Á4% (95% CI 33Á0-50Á2) at week 140.
Improvements in EQ-5D-3L visual analogue scale score and all individual domains were maintained steadily during years 1-3 ( Fig. S4 ; see Supporting Information). The mean visual analogue scale score (AE SD) with secukinumab 300 mg FI was 83Á8 AE 14Á8 at week 52, 83Á5 AE 15Á3 at week 104 and 83Á1 AE 16Á6 at week 140. Again, the group treated with 300 mg FI exhibited consistently greater improvements than the group receiving 300 mg RAN, which had mean visual analogue scale scores (AE SD) of 76Á2 AE 19Á7 at week 52, 77Á8 AE 17Á3 at week 104 and 80Á2 AE 15Á6 at week 140.
Safety
The most common adverse events in the overall study population were consistent with the adverse events reported in the SCULPTURE core study and with those reported in previous phase III studies. 6, 7 These included nasopharyngitis, upper respiratory tract infection and headache, with similar incidences in both treatment groups (Table 2) . With regard to adverse events of special interest, including Candida infections, serious infections, malignancy, neutropenia, inflammatory bowel disease and major adverse cardiovascular events, no new or unexpected findings compared with the SCULPTURE core study were observed up to 3 years of treatment. The nature and incidences of these adverse events were also consistent with observations from previous studies with secukinumab. 6 All of the cases of Candida infection (six with 300 mg FI; four with 300 mg RAN) were mild or moderate, and none led to study treatment discontinuation. No deaths were reported. Regarding immunogenicity, the number of patients receiving 300 mg FI who tested positive for antisecukinumab antibodies was 0 during treatment year 2 and two during treatment year 3. In both cases, the antidrug antibodies were associated with no pharmacokinetic abnormalities. No adverse events occurred that were potentially related to the presence of the antibodies, and although both patients tested positive for neutralizing antibodies, no reduction in therapeutic efficacy was observed. Similarly, in the 300 mg RAN group, no patient tested positive for antisecukinumab antibodies during year 2, and two tested positive during year 3. One of these patients was positive for neutralizing antibodies.
Discussion
These long-term data demonstrate that secukinumab 300 mg FI dosing maintained good efficacy out to 3 years of treatment in patients with moderate-to-severe plaque psoriasis, with six out of every 10 patients exhibiting clear or almost clear skin (PASI 90) at week 152. Notably, the mean absolute PASI in the 300 mg FI treatment arm remained in the range 2À4 during years 2 and 3 of treatment. The achievement and maintenance of an absolute PASI < 5 points is regarded as a strong indicator of the achievement of long-term psoriasis control. 18 Consistently with the product labelling, 300 mg administered in a 4-weekly maintenance dose provided better efficacy over time than an equivalent dose administered in a RAN regimen. Secukinumab 300 mg FI exhibited a similar degree of efficacy in both the as-observed and multiple-imputation analyses. The as-observed analysis, in which only patients remaining in the trial with efficacy data available were considered, assessed treatment efficacy in the subset of study patients who received secukinumab for the full 3 years of follow-up. The multipleimputation analysis evaluated efficacy 3 years after treatment initiation in the overall population of patients enrolled in the extension. The similarity of the results across the data analyses supports the robustness of the data.
The high degree and durability of psoriasis control attained with secukinumab were manifested in HRQOL, with approximately two-thirds of the 300 mg FI treatment group reporting no effect of skin disease on their lives (DLQI 0 or 1) throughout the follow-up period. Improvements in individual components of HRQOL, as measured on the DLQI and EQ-5D-3L, were maintained steadily over time in the secukinumab 300 mg FI treatment arm. Notably, a high proportion (> 77%) of patients in this group reported no impairment in the EQ-5D-3L domain of anxiety-depression from year 1 through year 3, an observation consistent with the small number who experienced depression as an adverse event in this study. Plaque psoriasis is known to be associated with a profoundly negative impact on patient psychological and emotional well-being. 19, 20 The treatment efficacy and improved HRQOL seen with secukinumab in the presence of a good safety profile may thus plausibly contribute to alleviating the psychosocial burden of psoriasis.
No new or unexpected safety signals were observed compared with the phase II and III studies. Similarly, no safety issues emerged over 3 years of treatment compared with the safety data seen during the 52-week SCULPTURE core study. A numerically low proportion of patients treated with secukinumab 300 mg FI were positive for antisecukinumab antibodies, and in all cases the antibodies were transient, no pharmacokinetic abnormalities or antibody-related adverse events were seen, and there was no impact on treatment efficacy. The incidence of immunogenicity in the 300 mg RAN group was similar.
A strength of this study is that patients were not required to be PASI 75 responders at week 52 of the core study to be eligible for the extension phase; accordingly, the long-term data presented here are for a broad group of patients. A limitation of this study is the stringent criteria for start of relapse, which were chosen to be greater than the natural variability in disease course and physician assessment. Patients receiving the RAN regimen therefore worsened considerably before becoming eligible for retreatment, which may have biased efficacy results against the RAN regimen.
Over 60 000 patients have been treated with secukinumab for psoriasis or psoriatic arthritis since this agent was first made available in the clinic (Novartis 2016, data on file). This extension study now provides evidence for the sustained efficacy and favourable safety profile of a secukinumab 300 mg FI regimen (i.e. dosed per label) in moderate-to-severe plaque psoriasis for up to 3 years. Furthermore, no drop-off in HRQOL improvement was seen with FI secukinumab dosing through long-term follow-up. The study data, which were collected in a population that was not using additional systemic psoriasis therapy and could apply topical treatments only under limited conditions, are thus very pertinent to treatment selection for a condition that typically requires longterm management. Additional extension data will further characterize the therapeutic profile of secukinumab over the long term. Change from baseline in EuroQol (EQ)-5D-3L visual analogue scale score (a) and proportions of patients reporting no impairment in EQ-5D-3L domains with secukinumab 300 mg (b) fixed interval and (c) retreatment as needed.
